Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

Molecule to Treat Various Risk Factors of Cardiometabolic Disease Goes into Clinic

  • Genfit reports the entry into Phase I trials of GFT505, the company’s molecule for the simultaneous treatment of several risk factors of cardiometabolic disease.

    According to a Genfit spokesperson, GFT505, a multimodal, pluripotent compound, acts on the molecular level by activating PPAR (peroxisome proliferator-activated receptors) nuclear receptors, which play a central role in the regulation of lipid metabolism and the control of glycemia.

    “With a completely original profile—Pan-sPPARm, selective PPAR modulator, with a preferential action on the PPAR alpha family—and evaluated by Genfit’s proprietary SNuRM technology platform, GFT505 targets a wide range of indications: mixed dyslipidemia, type II diabetes, and atherosclerosis,” explains Dean Hum, vp and CSO.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »